Periodic Reporting for period 1 - RV001 (RV001: An anti-metastatic cancer vaccine)
Reporting period: 2018-04-01 to 2018-09-30
RhoVac is developing the first therapeutic vaccine – RV001 – against initial formation and spread of metastatic cancer cells. The concept behind RV001 relies on the reprogramming of the patient own T cells to recognise and eliminate early stage metastatic cancer cells. Together with an unprecedented therapeutic potential in multiple cancer types, RV001 holds important competitive advantages, such as targeting a stage of the disease where there is currently no treatment available, high safety and cost-effectiveness.
Throughout the feasibility assessment in the SME instrument Phase 1, RhoVac aimed to i) do a market analysis, including definition of market; ii) engage with Key Opinion Leaders (KOLs) and strategic partners; iii) prepare the SME Instrument Phase 2 project; and iv) Develop a viable business plan.